{"type":"trials","record":{"id":42007,"source_id":"clinicaltrials-gov","external_id":"NCT06355830","title":"Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study","brief_summary":"Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD. Recruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC. Primary outcome: Identifying imaging predictors of iAMD progression.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Universidade Nova de Lisboa","enrollment":150,"countries":["Portugal"],"start_date":"2019-01-02","completion_date":"2026-06-01","last_update_date":"2024-04-09","source_url":"https://clinicaltrials.gov/study/NCT06355830","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"Imaging4iAMD","age_range":"55 Years to 95 Years","comparator":null,"organization":"Universidade Nova de Lisboa","interventions":["Orthoptic assessment (Outcome measure)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) from baseline — Months 0 (baseline),…","Change in Drusen morphology from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Subfoveal drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in other drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Drusen reflectivity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in other Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in ellipsoid zone disruption from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in hyperreflective foci from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in hyperreflective foci location (within 500-μm disc area) from baseline — Months 0 (baseline), 6, 12, 18, 24, 3…","Change in hyperreflective foci association to drusen from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and…","Progression to Moderate Vision Loss — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Geographic Atrophy (GA) Growth Rate — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Progression to Advanced AMD according to international classification/grading system — Months 0 (baseline), 6, 12, 18,…"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Orthoptic assessment (Outcome measure)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06355830","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-01-02 to 2026-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years to 95 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.906Z","intervention":["Orthoptic assessment (Outcome measure)"],"participants":150,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) from baseline — Months 0 (baseline),…","Change in Drusen morphology from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Subfoveal drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in other drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Drusen reflectivity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in other Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in ellipsoid zone disruption from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in hyperreflective foci from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Change in hyperreflective foci location (within 500-μm disc area) from baseline — Months 0 (baseline), 6, 12, 18, 24, 3…","Change in hyperreflective foci association to drusen from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and…","Progression to Moderate Vision Loss — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Geographic Atrophy (GA) Growth Rate — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48","Progression to Advanced AMD according to international classification/grading system — Months 0 (baseline), 6, 12, 18,…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42007","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}